AL Amyloidosis Market to Grow Rapidly During the Forecast Period – DelveInsight | Key Companies – Caelum Biosciences, Spectrum Pharmaceuticals, and Millennium Pharmaceuticals
DelveInsight’s “AL Amyloidosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the AL Amyloidosis Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The AL Amyloidosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
AL Amyloidosis: An Overview
Amyloid light-chain (AL) amyloidosis, also known as primary amyloidosis, is the most common form of systemic amyloidosis in the US. The disease is caused when a person’s antibody-producing cells do not function properly and produce abnormal protein fibres made of components of antibodies called light chains. The amyloid deposits in AL amyloidosis are not themselves cancerous; however, the condition may occasionally be associated with cancer called myeloma.
The survival of patients with amyloidosis is quite variable, with median survival ranging from 12 months to 18 months in different series, and largely depends on the number of organs involved and the severity of their involvement.
AL Amyloidosis Market Key Facts
According to a study conducted by Shimazaki et. al. (2019) titled, “Current diagnosis and treatment of AL amyloidosis in Japan: a nationwide epidemiological survey,” the incidence of AL amyloidosis, in Japan, was estimated to be 4.2/million person-years.
As per the National organization for Rare disease information, while the incidence is thought to be equal in males and females, about 60% of patients referred to amyloid centres are male. AL amyloidosis has been reported in individuals as young as 20 years of age but is typically diagnosed at about age 50–65.
According to the National Organization for Rare Disease, 60% of patients referred to amyloid centres are male.
Increased awareness of this unique histology has allowed for the development of drugs that are specific and has begun to shed light on the similarities and possible unique aspects of AL Amyloidosis. These factors, along with the expected launch of emerging therapies, will boost the market during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted AL Amyloidosis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the AL Amyloidosis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
AL Amyloidosis Epidemiology
The epidemiology section covers insights about the historical and current AL Amyloidosis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
AL Amyloidosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the AL Amyloidosis market or expected to get launched in the market during the study period. The analysis covers AL Amyloidosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the AL Amyloidosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/al-amyloidosis-market
AL Amyloidosis Therapeutics Analysis
There is no cure for patients with AL amyloidosis, but more frequently, patients go into remission with drug therapy. It is believed that the majority of patients surviving the first 6 months can often start recovering thereafter and can typically live normal or near-normal lives for years to come.
At present some of the key companies are diligently working towards the development of therapies for AL Amyloidosis. The launch of expected emerging therapies is expected to significantly impact the amyloid light chain (“AL”) amyloidosis market during the forecast period.
Some of the key companies in the AL Amyloidosis Market include –
AL Amyloidosis Therapies covered in the report includes:
And many others
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/al-amyloidosis-market
Table of Content
1. Key Insights
2. Executive Summary
3. AL Amyloidosis Competitive Intelligence Analysis
4. AL Amyloidosis Market Overview at a Glance
5. AL Amyloidosis Disease Background and Overview
6. AL Amyloidosis Patient Journey
7. AL Amyloidosis Epidemiology and Patient Population
8. AL Amyloidosis Treatment Algorithm, Current Treatment, and Medical Practices
9. AL Amyloidosis Unmet Needs
10. Key Endpoints of AL Amyloidosis Treatment
11. AL Amyloidosis Marketed Products
12. AL Amyloidosis Emerging Therapies
13. AL Amyloidosis Seven Major Market Analysis
14. Attribute Analysis
15. AL Amyloidosis Market Outlook (7 major markets)
16. AL Amyloidosis Access and Reimbursement Overview
17. KOL Views on the AL Amyloidosis Market.
18. AL Amyloidosis Market Drivers
19. AL Amyloidosis Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/al-amyloidosis-market
Other Latest Reports By DelveInsight
DelveInsight’s, “Bevacizumab Biosimilar Insight” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. The report also covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States
Published Wed, 16 Mar 2022 18:30:16 -0500